Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.31 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.30 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1614635 | 1.00 | SPHK1 (0.31) | SPHK1KEAP1NFE2L2HCAR2HCRTR2 | |
| SCHEMBL1614640 | 1.00 | SPHK1 (0.31) | SPHK1KEAP1NFE2L2HCAR2HCRTR2 | |
| SCHEMBL1614637 | 1.00 | SPHK1 (0.31) | SPHK1KEAP1NFE2L2HCAR2HCRTR2 | |
| SCHEMBL12714079 | 0.86 | SPHK1 (0.34) | SPHK1HCAR2HCRTR2 | |
| SCHEMBL3956953 | 0.82 | HCAR2 (0.34) | KEAP1NFE2L2HCAR2 | |
| SCHEMBL26531951 | 0.81 | SPHK1 (0.31) | SPHK1 | |
| SCHEMBL25251925 | 0.81 | SPHK1 (0.34) | SPHK1HCRTR2 | |
| SCHEMBL17212829 | 0.81 | SPHK1 (0.34) | SPHK1HCRTR2 | |
| SCHEMBL6979809 | 0.81 | SPHK1 (0.34) | SPHK1HCRTR2 | |
| SCHEMBL12534240 | 0.81 | SPHK1 (0.34) | SPHK1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309599-B2 | Synthesis of FR901464 and analogs with antitumor activity | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-11-13 | — | — | US | disclosed |
| US-20110086909-A1 | SYNTHESIS OF FR901464 AND ANALOGS WITH ANTITUMOR ACTIVITY | UNIVERSITY OF PITTSBURGH-- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2011-04-14 | — | — | US | disclosed |
| US-7825267-B2 | Synthesis of FR901464 and analogs with antitumor activity | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2010-11-02 | — | — | US | disclosed |
| US-20080096879-A1 | SYNTHESIS OF FR901464 AND ANALOGS WITH ANTITUMOR ACTIVITY | UNIVERSITY OF PITTSBURGH-- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096879-A1 | SYNTHESIS OF FR901464 AND ANALOGS WITH ANTITUMOR ACTIVITY | RBM17, SF3B1, RTCB | SPHK1 1268/4885KEAP1 1584/4885NFE2L2 2828/4885 |
| US-20110086909-A1 | SYNTHESIS OF FR901464 AND ANALOGS WITH ANTITUMOR ACTIVITY | RBM17, SF3B1, RTCB | SPHK1 1268/4885KEAP1 1584/4885NFE2L2 2828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.